Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
Adams, S., Loi, S., Toppmeyer, D., Cescon, D.W., De Laurentiis, M., Nanda, R., Winer, E.P., Mukai, H., Tamura, K., Armstrong, A., Liu, M.C., Iwata, H., Ryvo, L., Wimberger, P., Rugo, H.S., Tan, A.R., Jia, L., Ding, Y., Karantza, V., Schmid, P.
Published in Annals of oncology (01.03.2019)
Published in Annals of oncology (01.03.2019)
Get full text
Journal Article
1963 First prospective outcome data in 930 patients with more than 5 year median follow up in whom treatment decisions in clinical practice have been made incorporating the 21-Gene Recurrence Score
Stemmer, S, Steiner, M, Rizel, S, Ben-Baruch, N, Soussan-Gutman, L, Rosengarten, O, Geffen, D, Nisenbaum, B, Ryvo, L, Uziely, B, Fried, G, Svedman, C, Rothney, M, Klang, S, Kaufman, B, Isaacs, K, Evron, E, Zidan, J, Shak, S, Liebermann, N
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
Recurrence score results in elderly patients with estrogen receptor positive early breast cancer
Steiner, M, Ciuraru, N.B, Nisenbaum, B, Ryvo, L, Uziely, B, Geffen, D, Drumea, K, Leviov, M, Rizel, S, Stemmer, S
Published in Journal of geriatric oncology (01.10.2013)
Published in Journal of geriatric oncology (01.10.2013)
Get full text
Journal Article
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
Martín, Miguel, Lim, Elgene, Chavez-MacGregor, Mariana, Bardia, Aditya, Wu, Jiong, Zhang, Qingyuan, Nowecki, Zbigniew, Cruz, Felipe Melo, Safin, Rustem, Kim, Sung-Bae, Schem, Christian, Montero, Alberto J, Khan, Sarah, Bandyopadhyay, Reeti, Moore, Heather M, Shivhare, Mahesh, Patre, Monika, Martinalbo, Jorge, Roncoroni, Laura, Pérez-Moreno, Pablo Diego, Sohn, Joohyuk
Published in Journal of clinical oncology (27.03.2024)
Published in Journal of clinical oncology (27.03.2024)
Get full text
Journal Article
Abstract P1-07-14: Real-life analysis evaluating >1000 N0/N1mi estrogen receptor (ER)+ breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score (RS) result: Clinical outcomes with median follow up of > 9 years
Stemmer, SM, Rizel, S, Steiner, M, Geffen, DB, Soussan-Gutman, L, Bareket-Samish, A, McCullough, D, Svedman, C, Nisenbaum, B, Ryvo, L, Peretz, T, Fried, G, Rosengarten, O, Liebermann, N, Ben Baruch, N
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Get full text
Journal Article
Duration of response and tumor shrinkage with first-line ribociclib + letrozole in postmenopausal women with HR+, HER2– ABC
Janni, W., Alba Conejo, E., Bachelot, T., Diab, S., Gil-Gil, M., Beck, T.J., Ryvo, L., López, R., Tsai, M., Esteva, F.J., Zamora Aunon, M.P., Kral, Z., Ward, P., Richards, P., Pluard, T.J., Sutradhar, S., Miller, M., Campone, M.
Published in Annals of oncology (01.09.2017)
Published in Annals of oncology (01.09.2017)
Get full text
Journal Article
Abstract PD6-10: KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1–positive, previously untreated, metastatic triple-negative breast cancer (mTNBC)
Adams, S, Loi, S, Toppmeyer, DL, Cescon, DW, De Laurentiis, M, Nanda, R, Winer, EP, Mukai, H, Tamura, K, Armstrong, AC, Liu, MC, Iwata, H, Ryvo, L, Wimberger, P, Rugo, HS, Tan, A, D'Aquanno, C, Ding, Y, Karantza, V, Schmid, P
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Get full text
Journal Article
Abstract OT2-01-04: SOLAR-1: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy
Andre, F, Kaufman, B, Juric, D, Ciruelos, EM, Iwata, H, Mayer, IA, Rugo, HS, Conte, P, Liobl, S, Rubovszky, G, Inoue, K, Tesch, H, Lu, Y-S, Ryvo, L, Longin, A-S, Mills, D, Wilke, C, Germa, C, Campone, M
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Get full text
Journal Article
A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)
André, F., Kaufman, B., Juric, D., Ciruelos, E., Iwata, H., Mayer, I.A., Conte, P., Rugo, H.S., Loibl, S., Rubovszky, G., Tesch, H., Inoue, K., Lu, Y.-S., Ryvo, L., Longin, A.-S., Mills, D., Wilke, C., Germa, C., Campone, M.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article
137TiP A phase III study of alpelisib and fulvestrant for hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)
Iwata, H., Rubovszky, G., Loibl, S., Ciruelos, E., Campone, M., Juric, D., Rugo, H., Mayer, I., Conte, P.F., Kaufman, B., Inoue, K., Tesch, H., Li, Y.-S., Mingorance, I.D., Ryvo, L., Iwase, H., Longin, A.-S., Mills, D., Wilke, C., Andre, F.
Published in Annals of oncology (01.12.2016)
Published in Annals of oncology (01.12.2016)
Get full text
Journal Article
137TiP A phase III study of alpelisib and fulvestrant for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)
Iwata, H., Rubovszky, G., Loibl, S., Ciruelos, E., Campone, M., Juric, D., Rugo, H., Mayer, I., Conte, P.F., Kaufman, B., Inoue, K., Tesch, H., Li, Y-S., Mingorance, I.D., Ryvo, L., Iwase, H., Longin, A-S., Mills, D., Wilke, C., André, F.
Published in Annals of oncology (01.12.2016)
Published in Annals of oncology (01.12.2016)
Get full text
Journal Article
Abstract P5-20-06: RAD001 (Everolimus) in combination with Letrozole in the treatment of postmenopausal women with estrogen receptor positive Metastatic Breast cancer after failure of hormonal therapy – a phase II study
Safra, T, Kaufman, B, Ben, Baruch N, Kadouri-Sonenfeld, L, Nisenbaum, B, Greenberg, J, Ryvo, L, Yerushalmi, R, Evron, E
Published in Cancer research (Chicago, Ill.) (15.12.2012)
Published in Cancer research (Chicago, Ill.) (15.12.2012)
Get full text
Journal Article
Abstract P5-08-02: Real-life analysis evaluating 1594 N0/Nmic breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score result: 5-year KM estimate for breast cancer specific survival with recurrence score results ≤30 is >98
Stemmer, SM, Steiner, M, Rizel, S, Soussan-Gutman, L, Geffen, DB, Nisenbaum, B, Ben-Baruch, N, Isaacs, K, Fried, G, Rosengarten, O, Uziely, B, Svedman, C, Rothney, M, Klang, SH, Ryvo, L, Kaufman, B, Evron, E, Zidan, J, Shak, S, Liebermann, N
Published in Cancer research (Chicago, Ill.) (15.02.2016)
Published in Cancer research (Chicago, Ill.) (15.02.2016)
Get full text
Journal Article
A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study
Ron, Ilan G, Sarid, David, Ryvo, Larisa, Sapir, Einat Even, Schneebaum, Shlomo, Metser, Ur, Asna, Noam, Inbar, Moshe J, Safra, Tamar
Published in Melanoma research (01.02.2006)
Published in Melanoma research (01.02.2006)
Get more information
Journal Article